Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
- Net sales of DARZALEX® in the third quarter of 2023 totaled USD 2,499 million
- Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen)
COPENHAGEN, Denmark; October 17, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 2,499 million in the third quarter of 2023. Net trade sales were USD 1,369 million in the U.S. and USD 1,130 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO™) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: firstname.lastname@example.org
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: email@example.com
This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect®and KYSO™. DARZALEX® and DARZALEX FASPRO® are trademarks of Johnson & Johnson.
Company Announcement no. 43
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Carl Jacobsens Vej 30
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
VALOE EXTENDS THE SUBSCRIPTION PERIOD OF THE CONVERTIBLE BOND 1/202330.11.2023 15:15:00 CET | Press release
Valoe Corporation Stock Exchange Release 30 November 2023 at 16.15 (Finnish time) The Board of Directors of Valoe Corporation has resolved to extend the subscription period of the Convertible Bond 1/2023 disclosed on 14 July 2023 until 29 December 2023 at 6.00 pm. In Mikkeli on 30 November 2023 Valoe Corporation BOARD OF DIRECTORS For more information: CEO Iikka Savisalo, Valoe Corporation tel. +358 40 521 6082 email: firstname.lastname@example.org Distribution: Nasdaq Helsinki Oy Main media www.valoe.com Valoe Corporation specializes in the clean energy, especially in photovoltaic solutions. Valoe provides PV technology based on its own back contact technology and related projects, project design and technology consulting. Valoe also provides manufacturing technology for PV modules, module manufacturing lines, modules and key components for modules, as well as IBC solar cells manufactured at the Company’s factory in Lithuania. Valoe is headquartered in Mikkeli, Finland, with production faci
Scatec awarded battery storage project for 103 MW in government tender in South Africa30.11.2023 14:53:04 CET | Press release
Oslo, 30 November 2023: Scatec ASA has been awarded preferred bidder status for the Mogobe (Ferrum) battery energy storage project totalling 103 MW/ 412 MWh under the first bid window of the Battery Energy Storage Independent Power Producer Procurement Programme (BESIPPPP) in South Africa, by the Department of Mineral Resources and Energy. Scatec will dispatch power under a 15-year power purchase agreement (PPA). “This marks another significant achievement for Scatec in South Africa and for the renewable energy transition in the country. Today’s award reaffirms our standing as a leading renewable energy player in South Africa. We applaud the South African government’s commitment and dedication to the battery storage procurement programme,” says Scatec CEO Terje Pilskog. Building on the experience garnered from our hybrid solar and battery storage projects at Kenhardt, we have established ourselves as a frontrunner in the dispatchable renewable energy landscape of South Africa and the A
Correction: New terms for DK0009414252 only english version30.11.2023 14:47:05 CET | Press release
To Nasdaq Copenhagen A/S 30th November 2023 Announcement no. 111/2023 Final terms for bonds to be listed 5thDecember 2023 On 5th December 2023, Jyske Realkredit A/S will be listing new Covered Bonds (SDO). Final terms for the bonds are attached to this announcement. The full prospectus for the Bond consist of the attached final terms and the previously disclosed ”Base Prospectus for the issue of Covered Bonds (SDO), Mortgage bonds (“RO”) and Mortgage Bonds (RO) and bonds issued pursuant to Section 15 of the Danish Mortgage-Credit Loans and Mortgage-Credit Bonds etc. Act (Section 15 Bonds).”, dated June 29th, 2023. Jyske Realkredit’s base prospectus is available on Jyske Realkredit’s home page jyskerealkredit.com Yours sincerely, Jyske Realkredit A/S www.jyskerealkredit.com Please observe that the Danish version of this announcement prevails. Attachments DK0009414096 - Final terms series 1 321.E.ok.25 IT1DK0009414179 - Final terms series 1 321.E.26 IT1DK0009414252 - Final terms series 1
Correction: Kun korrektion i den engelske version30.11.2023 14:47:05 CET | pressemeddelelse
, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Til Nasdaq Copenhagen A/S 30. november 2023 Meddelelse nr. 111/2023 Endelige vilkår for nye obligationer der noteres den 5. december 2023 Jyske Realkredit noterer den 5. december 2023 nye Særligt Dækkede Obligationer (SDO). Med denne meddelelse følger de endelige vilkår for obligationerne. Det samlede prospekt for obligationerne består af vedlagte endelige vilkår og det tidligere offentliggjorte ”Basisprospekt for udstedelse af Særligt Dækkede Obligationer (SDO), Realkreditobligationer (RO) og obligationer i medfør af § 15 i lov om realkreditlån og realkreditobligationer m.v. (§ 15 Obligationer)”, dateret 29. juni 2023. Jyske Realkredits basisprospekt er tilgængeligt på Jyske Realkredits hjemmeside jyskerealkredit.dk. Venlig hilsen Jyske Realkredit www.jyskerealkredit.dk Vedhæftede filer DK0009414252 - Endelige vilkår serie 1 321.E.EUR.26 IT1DK0009414096 - Endelige vilkår serie 1 321.E.ok.25 IT1DK0009414179 - Endelige vilkår serie 1 321.E.26 IT1
FRO – Q3 2023 Presentation30.11.2023 14:40:31 CET | Press release
Please find enclosed the presentation of Frontline plc´s third quarter 2023 results to be held on the webcast / conference call 30 November, 2023 at 15:00 CET. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. Attachment Presentation Q3 2023